National Cancer Institute (NCI)
NCI Public Inquiries Office
Building, 31, Room 10A03<br>31 Center Drive, MSC 2
Bethesda
Maryland
20892-2580
United States
Tel: 301-435-3848
Website: http://www.nci.nih.gov/
815 articles with National Cancer Institute (NCI)
-
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
3/14/2023
Eureka Therapeutics, Inc. today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS ® T-cell receptor platform.
-
City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute
2/16/2023
City of Hope announced that its comprehensive cancer center has received the highest rating possible for a U.S. cancer center — "exceptional" — by the National Cancer Institute, the federal government's principal agency for cancer research and training.
-
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
2/14/2023
Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute, an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study.
-
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
2/6/2023
Sensei Biotherapeutics, Inc. today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody.
-
HCW Biologics Enters CRADA with National Cancer InstituteNCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer
12/8/2022
HCW Biologics Inc. today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.
-
Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer
11/29/2022
Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.
-
Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy
11/29/2022
Turnstone Biologics Corp today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to evaluate the generation of tumor-reactive T-cells, which form the basis of Turnstone’s tumor-infiltrating lymphocyte platform.
-
Waterdrop Launches Insurance against Breast Cancer Recurrence
11/4/2022
The National Cancer Institute's SEER statistics show that breast cancer recurrence rate is as much as 30%.
-
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform
10/31/2022
Mosaic ImmunoEngineering today announced that two research grants totaling $4.3 million from the National Cancer Institute (NCI) were awarded to the Company's collaborating scientists and their respective academic institutions.
-
Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform
10/25/2022
Modifi Biosciences has been selected by the National Cancer Institute for a Fast-Track Small Business Innovation Research Award of $2.4 million to further advance its novel precision oncology platform into the clinic.
-
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
10/18/2022
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS ® T Cell Therapy for Neuroblastoma.
-
Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit
9/15/2022
Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit.
-
NIH Awards AVM Biotechnology SBIR Grant to Study AVM0703 Combined with Standard of Care in Non-Hodgkin’s Lymphoma (NHL) to Improve Complete Response Rates Without Additional Toxicities
8/25/2022
AVM Biotechnology today announced the award of a third Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).
-
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025
6/27/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) .
-
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
6/14/2022
Immunicom, Inc., a privately held clinical-stage biotechnology company with a transformative immuno-oncology platform, has been awarded $2 million by the National Cancer Institute and National Institutes of Health to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas.
-
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
4/19/2022
NextCure, Inc. announced the publication of a paper titled “Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication” in the Journal of Clinical Investigation.
-
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.
-
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here's how this consortium will help researchers.
-
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
2/3/2022
Castle Biosciences, Inc. today announced a collaboration with the National Cancer Institute (NCI) to link DecisionDx®-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program’s registries on cutaneous melanoma (CM) cases.
-
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
1/11/2022
Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.